MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Xu, Haitao ^a   Zhao, Liang ^a   Fang, Qiuju ^b   Sun, Jianmin ^a   Zhang, Songyan ^a   Zhan, Chao ^a   Liu, Shujie ^a   Zhang, Yubao ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG PROVINCIAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 338 3P; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; HIF1A PROTEIN, HUMAN; MESSENGER RNA; MIRN338 MICRORNA, HUMAN; NICOTINAMIDE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

MUS MUSCULUS;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NIACINAMIDE; PHENYLUREA COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919782645     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115565     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Livraghi T, Makisalo H, Line PD (2011) Treatment options in hepato cellular carcinoma today. Scand J Surg 100: 22-29.
3. El-Serag HB (2011) Hepato cellular carcinoma. N Engl J Med 365: 1118-1127.
4. Palmer DH (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 2498; author reply 2498-2499.
5. Asghar U, Meyer T (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56: 686-695.
6. Vaupel P (1977) Hypoxia in neoplastic tissue. Micro vasc Res 13: 399-408.
7. Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 3: 647-654.
8. Nath B, Szabo G (2012) Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 55: 622-633.
9. Rosmorduc O, Housset C (2010) Hypoxia: A link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 30: 258-270.
10. Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 22: 1178-1182.
11. Tak E, Lee S, Lee J, Rashid MA, Kim YW, et al. (2011) Human carbonyl reductase 1 up regulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol 54: 328-339.
12. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454.
13. Chen C, Wang J, Liu R, Qian S (2012) RNA interference of hypoxia-inducible factor-1 alpha improves the effects of transcatheter arterial embolization in rat liver tumors. Tumour Biol 33: 1095-1103.
14. Liu LP, Ho RL, Chen GG, Lai PB (2012) Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: Implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18: 5662-5671.
15. Yang W, Sun T, Cao J, Fan S (2011) Hypoxia-inducible factor-1alpha downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and enhances radiosensitivity in chemical hypoxic human hepatoma SMMC-7721 cells. Cancer Biother Radio pharm 26: 565-571.
16. Semenza GL (2002) HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8: S62-S67.
17. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
18. Zamore PD, Haley B (2005) Ribo-gnome: The big world of small RNAs. Science 309: 1519-1524.
19. Calin GA, Croce CM (2006) Micro RNA-cancer connection: The beginning of a new tale. Cancer Res 66: 7390-7394.
20. Liang Y, Zheng T, Song R, Wang J, Yin D, et al. (2013) Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology 57: 1847-1857.
21. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
22. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS (2008) PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 105: 2622-2627.
23. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, et al. (2004) hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126: 231-248.
24. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, et al. (2009) Accurate micro RNA target prediction correlates with protein repression levels. BMC Bioinformatics 10: 295.
25. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, et al. (2009) DIANA-micro T web server: Elucidating micro RNA functions through target prediction. Nucleic Acids Res 37: W273-W276.
26. Poller B, Wagenaar E, Tang SC, Schinkel AH (2011) Double-trans duced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 8: 571-582.
27. Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, et al. (2014) MicroRNA-338-3p Inhibits Colorectal Carcinoma Cell Invasion and Migration by Targeting Smoothened. Jpn J Clin Oncol 44: 13-21.
28. Chen X, Pan M, Han L, Lu H, Hao X, et al. (2013) miR-338-3p suppresses neuro blastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett 587: 3729-3737.
29. Li P, Chen X, Su L, Li C, Zhi Q, et al. (2013) Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 8: E66782.
30. Won KY, Kim YW, Kim HS, Lee SK, Jung WW, et al. (2013) MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum Pathol 44: 1648-1655.
31. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, et al. (2005) Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42: 358-364.
32. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, et al. (1998) Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepato cellular carcinoma. Cancer Res 58: 348-351.
33. Mazure NM, Nguyen TL, Danan JL (2001) Severe hypoxia specifically down regulates hepatocyte nuclear factor-4 gene expression in HepG2 human hepatoma cells. Tumour Biol 22: 310-317.
34. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, et al. (2000) Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 19: 4621-4631.
35. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
36. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
37. Fu X, Tan D, Hou Z, Hu Z, Liu G (2012) miR-338-3p Is Down-Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 39-UTR Region of CyclinD1. International Journal of Molecular Sciences 13: 8514-8539.
38. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, et al. (2011) miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 225: 463-472.
39. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
40. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A (2001) Regulation of glut1 mRNA by hypoxiainducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276: 9519-9525.
41. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394.
42. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
43. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
44. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
45. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579.
46. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
47. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
48. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, et al. (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947-959.
49. Roberts WG, Palade GE (1997) Neo vasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772.
50. Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, et al. (1996) The vesiculo-vacuolar organelle (VVO): A distinct endothelial cell structure that provides a trans cellular pathway for macromolecular extra vasation. J Leukoc Biol 59: 100-115.
51. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, et al. (1992) Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 667: 101-111.
52. Olson AL, Pessin JE (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16: 235-256.
53. Fardel O, Lecureur V, Guillouzo A (1996) The P-glycoprotein multidrug transporter. Gen Pharmacol 27: 1283-1291.
54. Goldstein LJ (1996) MDR1 gene expression in solid tumours. Eur J Cancer 32A: 1039-1050.
55. Jin S, Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyl transferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384.
56. Ogretmen B, Safa AR (1999) Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 38: 2189-2199.
57. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) Micro RNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903.
58. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, et al. (2008) Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-33405.
59. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.